Ankit Malhotra serves as Global Head of Genomics Strategy and Solutions at Amazon Web Services( AWS), where he partners with organizations across the healthcare and life sciences industries to support the global delivery of precision medicine. He focuses on the stewardship of the digital infrastructure and analytical capabilities required to translate complex biological information into individualized patient care. His approach emphasizes providing the technical stability and scalability necessary for clinicians and researchers to collaborate effectively on a global scale. With a foundation in research from the University of Virginia and The Jackson Laboratory, Dr. Malhotra is dedicated to ensuring that the scientific community has the reliable tools and secure data environments needed to improve patient outcomes through personalized health.
Miguel Sena-Esteves is Professor of Neurology at the University of Massachusetts Chan Medical School and a leading expert in gene therapy for neurological disorders. His research focuses on the development of viral vector – based strategies, particularly adeno-associated virus( AAV) platforms, for the treatment of inherited diseases of the central nervous system. Dr. Sena-Esteves has made significant contributions to advancing gene delivery technologies and translating these approaches toward clinical application. His work spans vector engineering, preclinical disease models, and the development of therapies for rare neurogenetic conditions. He is widely recognized for his leadership in neurogenomics and gene therapy.
Boris Kantor is Director of the Viral Vector and Genome Editing Core at the Florida Institute for Pediatric Rare Diseases and Professor of Biomedical Sciences at the Florida State University College of Medicine. His research focuses on the development of gene therapy and genome editing strategies for neurological and genetic disorders, with particular emphasis on viral vector engineering and targeted gene delivery. Dr. Kantor’ s work spans vector design, preclinical disease models, and translational studies aimed at advancing novel therapeutics toward clinical application. He has published extensively and is actively engaged in collaborative efforts to develop next-generation gene therapy platforms for rare pediatric diseases.
Barry Byrne is Associate Chair of Pediatrics and Director of the Powell Gene Therapy Center at the University of Florida, where he leads multidisciplinary efforts in translational gene therapy. His work focuses on the development and clinical application of gene therapies for inherited disorders, particularly neuromuscular and metabolic diseases. Dr. Byrne has played a leading role in advancing AAV – based therapeutics from preclinical studies to human clinical trials. His research integrates vector development, disease modeling, and clinical translation, with the goal of bringing transformative therapies to patients with rare genetic conditions. He is widely recognized for his leadership in gene therapy.
04